TF and neoplasm: The OS and PFS survival curves for the MAF analyses were very similar to those with DELFI-TF, with baseline MAF values for tumor fraction assessment showing similar distinction in median OS (35.7 vs 19.0 months, HR = 2.82, 95% CI = 1.31-6.07, p < 0.01, log-rank) and median PFS (14.37 vs 8.28 months, HR = 2.82, 95% CI 1.46–5.45, p < 0.01, log-rank) (Fig. 3d and Supplementary Fig. 7).